A Due Diligence Perspective for 2027: Where SMEs, Academics and Commercialisation Officers Now Meet

In May 2025, I wrote that we were witnessing a fundamental restructuring of the small and mid-market business landscape. Eighteen months on, that restructuring is no longer a forecast — it is the operating environment. And something else has happened that few predicted: the due diligence standards once reserved for private equity targets are now being applied to university spinouts, licensing deals and research commercialisation projects.

If you are an SME owner, an academic founder, or a commercialisation officer inside a university or research institute, you are now — whether you realise it or not — playing in the same market, judged by the same investors, against the same benchmarks.

Here is what our due diligence work is telling us as we move through 2026 and plan for 2027.

The Three Evolutionary Paths, Revisited

Our original framework categorised SMEs into three paths: acquisition targets, franchise candidates, and independent survivors. The framework still holds, but the criteria have hardened.

1. Acquisition Targets — now filtered through an AI lens. The dominant question in every 2026 deal room is no longer “does this business have recurring revenue?” but “is this business AI-resilient or AI-exposed?” Buyers and sponsors are explicitly assessing whether a target’s margins, delivery model and competitive moat survive widespread AI adoption. Assets judged AI-resilient are attracting competitive bidding; those at risk of disruption are struggling to find buyers at any sensible multiple. With private equity funds under pressure to exit ageing portfolios and 2026 shaping up as the year of the corporate carve-out, there is genuine buyer appetite — but it is ruthlessly selective. Quality over quantity is the pattern: UK deal volumes fell through 2025 while average deal sizes surged.

2. Franchise and Licensing Candidates — the model has broadened. Franchising remains attractive for standardised service businesses, but we now see a parallel path emerging: licensing. Companies increasingly license technology and software rather than acquire outright, partly to sidestep valuation and regulatory friction. For SMEs with proprietary processes or tools — and for universities holding IP — this creates a route to revenue that did not meaningfully exist in the lower mid-market three years ago.

3. Independent Survivors — smaller in number, stronger in position. Deep niche specialisation plus pricing power still works. But the tax environment is squeezing the “hold indefinitely” option: with Business Asset Disposal Relief rising again to 18% in April 2026, many owners brought forward exit decisions, and those who remain independent are doing so as a deliberate strategy, not a default.

The New Entrants to This Market: Academics and Spinouts

The most significant structural change since our 2025 analysis is the maturing of the UK’s research commercialisation ecosystem into a genuine asset class.

The Royal Academy of Engineering’s Spotlight on Spinouts 2026 report shows the combined enterprise value of UK spinouts has grown 2.8-fold since 2020 to roughly £49 billion, with around 2,000 spinouts created since 2010 generating 27,000 jobs. The report per se is a pleasure to read, confirming the UK’s great potential. In 2025, two of Europe’s six billion-dollar spinout exits came from a single university — Oxford — with OrganOx acquired for around $1.5 billion and Oxford Ionics for around $1.1 billion. Just as importantly, activity is spreading well beyond the golden triangle, with Bristol, Manchester, Sheffield, Dundee and Edinburgh all generating serious value.

Three implications for three audiences

For academics: university equity stakes have fallen to around 16% on average — the lowest in a decade — following the reforms triggered by the 2023 independent review. Founding a spinout has never offered better founder economics. But the same report found that founder equity splits are frequently unequal, highly variable, and negotiated without clear guidance. Treat your cap table with the same rigour you would apply to your data: investors certainly will.

For commercialisation officers: the sector’s acknowledged weakness is speed. Spinouts still take 12 to 18 months to launch, and as the Academy itself has warned, that pace no longer matches the opportunity. Meanwhile, shared technology transfer office models — such as the Research England-funded Wessex regional pilot — are proving that smaller institutions can pool resources to build scale. The question for 2027 is not whether your institution has a TTO, but whether your commercialisation pathway can move at investor speed.

For SME owners: these spinouts are not an academic curiosity — they are your future competitors, acquisition targets, and partners. An SME that builds a licensing or joint-development relationship with a research institution acquires an innovation pipeline it could never fund alone.

The Blind Spot in the £49 Billion: SHAPE Ventures

Here is what the headline spinout figures will not tell you: 96% of that £49 billion sits in high-tech companies. Read quickly, that looks like proof that arts, humanities and social sciences research does not commercialise. Read carefully; it reveals something else — a measurement failure, not a market failure.

UKRI’s own data digest on the new spin-out register concedes that around 60% of spinouts originating from arts, humanities and social sciences backgrounds have unknown sectoral data. The ventures exist; the ecosystem simply was not built to count them. The sector now has a name for these disciplines — SHAPE (Social Sciences, Humanities and the Arts for People and the Economy) — and the evidence, where it has been gathered, is telling:

• Gravity Sketch, a spinout from the Royal College of Art, built a VR-based 3D design platform now used by Ford, Adidas and Reebok, and raised a $33 million Series A. It is UKRI’s own flagship example that arts-origin ventures can scale.
• The University of Bristol — the same institution ranked top outside the golden triangle for spinout value — launched twelve SHAPE social venture spinouts in late 2025 alone.
• Oxford’s social science spinouts span policy advice, economic development, education and data privacy, and research from the Aspect network (the UKRI-funded consortium for social science commercialisation) found roughly half of such projects become social ventures while the other half are conventional for-profit companies.

Why the invisibility?

Because SHAPE research does not follow the pathway that technology transfer offices were built around: patent, then licence or spin out, then venture capital. Its scalable assets are measurement methodologies, data-driven toolkits, behavioural frameworks and content — assets that are licensed rather than patented, and monetised through consultancy-style and recurring-revenue models. As one Aspect programme leader has pointed out, SHAPE research is being commercialised at enormous scale — by the McKinseys, Deloittes and law firms of the world. The value is real; it is simply leaking out of the institutions that created it.

This is precisely why the shared, sector-specific technology transfer models now being piloted matter beyond their headline purpose. The Royal Academy of Engineering has explicitly noted that sector-wide shared TTOs may be particularly relevant to spinouts from the social sciences, humanities and the arts, and Research England has allocated over £4.7 million to thirteen collaborations involving forty-nine higher education providers. Add to this the government’s acceptance that REF 2028 guidance should strongly emphasise spinouts and social ventures as a form of research impact, and the incentive structure for SHAPE academics is quietly being rewritten.

For SHAPE academics: your commercialisation route probably is not a patent. Map your research to a licensable asset — a methodology, a diagnostic, a toolkit, a dataset — and note that a social venture structure may fit your work better than a conventional company. Both now count as impact.

For commercialisation officers: if your office’s pipeline is 100% STEM, you do not have a STEM-strong institution — you have a SHAPE-blind process. Building a parallel pathway for licensing-led and social-venture models is one of the few genuinely uncontested differentiators left in the sector.

For SME owners: SHAPE ventures are natural partners, not curiosities. A behavioural science toolkit, a design methodology or an education product can be licensed into your business at a fraction of the cost of building it — and the creative and knowledge-services businesses that dominate this space are, not coincidentally, the classic profile of the independent survivor.

The Due Diligence Checklist for 2027

Our assessment framework has evolved again. Whether we are evaluating a family-owned manufacturer or a quantum spinout, we now test:

AI Position (the new first question)

• AI-resilience of the core revenue model — what happens to your margins when your customers adopt AI?
• Practical AI deployment, not pilots: UK government research published in early 2026 confirmed SME adoption was low and fragmented through 2025, which means genuine, embedded adoption is now a differentiator rather than table stakes
• Data foundations clean enough to make AI tools actually work

Financial Architecture

• Audit-ready financials and clean cap tables (for spinouts: documented, defensible founder equity splits)
• Recurring or contractual revenue components
• A realistic view of employment cost exposure, which continues to weigh on SME margins

Strategic Positioning

• A definable moat that survives both AI disruption and better-capitalised consolidators
• Documented IP ownership — a chronic weak point in university-adjacent ventures
• A credible exit or scaling pathway, on paper, readily available. This can change, be adapted or scrapped, but it has to exist.

The Investor Perspective, Updated

Capital continues to move downstream: roughly half of the first-time private equity funds closed in 2025 targeted the lower middle market and SME segment, and search funds remain active acquirers of well-documented small businesses. At the same time, spinout-focused vehicles are appearing at scale — including a £300 million investment vehicle launched by the SETsquared university partnership with QantX.

The message is the same for a workshop in the Midlands and a lab in Dundee: sophisticated capital is looking at you, and it arrives with a checklist.

Actionable Guidance for 2026–2027

SME owners: re-run the three-path assessment, but add the AI-resilience question first. Professionalise your reporting now; the buyers arriving in 2027 will not wait for you to tidy up.

Academics: understand your institution’s equity policy before you negotiate, document founder roles and splits early, and treat commercial readiness as part of the research project, not an afterthought.

Commercialisation officers: benchmark your spinout timelines against the 12–18-month sector average and set a target to beat it. Explore shared-service and regional models where scale is the constraint. And prepare your academic founders for investor-grade diligence before the first term sheet, not after.

The Convergence Is the Opportunity

The boundary between ‘small business’ and ‘research venture’ is dissolving — and not only in the laboratory sciences. The SME that partners with a university gains innovation capacity; the spinout that adopts SME operational discipline gains investability; the commercialisation office that thinks like a deal team gains speed; and the institution that builds a genuine pathway for its SHAPE researchers gains an asset class its competitors are still failing to count.

The difference between a successful transition and a missed window, in 2027 as in 2025, comes down to preparation and strategic foresight. Only now, the window moves faster.

Request access to our investor briefings, or book an introductory call to discuss how these trends affect your sector, institution or portfolio.